1. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study 
T.J. Schnitzer, A. Kivitz, H. Frayssinet, B. Duquesroix 
Osteoarthritis and Cartilage 
Volume 18, Issue 5, Pages (May 2010)
DOI: /j.joca
Copyright © 2010 Osteoarthritis Research Society International Terms and Conditions

2. Fig. 1
Patient disposition (ITT population). Note: violation of eligibility criteria includes patients who were found not to meet the study inclusion/exclusion criteria.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2010 Osteoarthritis Research Society International Terms and Conditions

3. Fig. 2
LS Mean and 95% CI change from baseline to Weeks 2, 6 and 13 in WOMAC™ pain subscale, WOMAC™ function subscale and patient's overall rating of disease status (ITT population) using LOCF (without baseline carried forward). P-value and 95% CI are from pairwise contrasts from an ANCOVA model with baseline as covariate and with treatment as a factor. P< for all comparisons of naproxcinod 750mg vs placebo; P≤ for all comparisons of naproxcinod 375mg vs placebo.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2010 Osteoarthritis Research Society International Terms and Conditions

4. Fig. 3
Difference in LS Mean changes (95% CI) from baseline in post-dose SBP and DBP at Week 13 (safety population).
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2010 Osteoarthritis Research Society International Terms and Conditions